Prostate cancer remains a significant cause of cancer-related deaths in men in the United States.
Significant advances in the treatment of metastatic castration-resistant prostate cancer have been made in recent years with the arrival of new therapeutic targets and options. The definition of progression of disease must be thought of in the context of clinical symptoms and radiographic evidence rather than as changes in prostate-specific antigen (PSA). Ultimately, the use of PSA criteria alone should not be used to determine the progression of disease; instead, PSA should be evaluated in combination with other clinical data.
Written by:
Karzai FH, Madan RA, Figg WD. Are you the author?
Medical Oncology Service, National Cancer Institute, Bethesda, Maryland.
Reference: South Med J. 2015 Apr;108(4):224-8.
doi: 10.14423/SMJ.0000000000000266
PubMed Abstract
PMID: 25871992